Peptides for sleep: what actually has human evidence (and what doesn't)

Search “peptides for sleep” and you will be told, confidently, that a short list of injectables can deepen your sleep, lengthen slow-wave sleep, or reset a broken night. The list is real — DSIP, the growth-hormone-axis peptides, and calming peptides like Selank all get promoted for sleep. What is not real is the implied evidence base. This page grades each one by the only thing that matters: controlled human sleep data. The honest headline is that no peptide is an evidence-based sleep therapy, and the proven levers live elsewhere.

DSIP: the flagship, and its sparse record

Delta sleep-inducing peptide (DSIP) is the peptide most tightly associated with sleep — the name alone does most of the marketing. It was isolated decades ago and drew clinical interest in the 1980s as a possible treatment for insomnia and disrupted sleep timing.^[1] That interest is exactly why it still headlines “peptides for sleep” lists today.

The problem is what happened when it was actually tested. In the best-designed human study — a double-blind, matched-pairs trial in 16 chronic insomniac patients with polysomnography — DSIP produced modestly higher sleep efficiency and shorter sleep latency versus placebo, but the effects were statistically weak, subjective sleep quality did not change, and the authors concluded that short-term DSIP treatment of chronic insomnia was “not likely to be of major therapeutic benefit.”^[2] That is the flagship peptide's strongest human result. The broader picture — what DSIP is, what the rest of the literature shows, and why the enthusiasm outran the data — is laid out in our DSIP evidence review. The short version: dated, sparse, and unconvincing.

The GH-axis peptides: a mechanism, not an outcome

Sermorelin, CJC-1295 and ipamorelin are not sleep drugs — they are growth-hormone secretagogues. The sleep pitch rests on a genuine piece of physiology: the largest natural pulse of growth hormone is released during deep, slow-wave sleep, so the two are biologically coupled. The marketing then runs the logic backwards, assuming that pushing the GH axis with a peptide will push deep sleep up. That inference is where the evidence gets thin.

When researchers have actually given GH-releasing hormone (GHRH) and measured sleep, the effect is real but conditional, not a reliable sleep aid. In a controlled study, GHRH enhanced non-REM sleep during recovery after sleep deprivation — but the same body of work describes a sex difference, with GHRH promoting sleep in men while impairing it in women.^[3] And the assumption that “more GH means more deep sleep” fails outright with stronger secretagogues: hexarelin, a synthetic GH secretagogue, sharply raised growth hormone yet decreased slow-wave sleep and delta power in healthy volunteers.^[4] In other words, driving GH release does not dependably buy you deeper sleep, and can do the opposite. There is no controlled trial showing that sermorelin, CJC-1295 or ipamorelin improves sleep as a clinical outcome — the claim is built on a mechanism, not on measured sleep.

Selank and the “calming peptide” angle

Selank shows up on sleep lists by association: it is promoted as an anxiolytic, and anxiety wrecks sleep, so the leap to “sleep aid” is easy to make in a sales page. But association is not evidence. There is no controlled human trial measuring Selank against a sleep outcome — sleep latency, sleep efficiency, slow-wave sleep, or an insomnia scale. What the human record actually contains is covered in our Selank evidence review, and it does not support using it as a sleep therapy. Treating an anxiolytic claim as a sleep claim is exactly the kind of substitution to be skeptical of.

The honest bottom line

Put the three together and the pattern is consistent: a flagship peptide (DSIP) with a weak, dated human record; a class (GH-axis peptides) sold on a mechanism its own data undercut; and a calming peptide (Selank) with no sleep-outcome trial at all. None clears the bar of an evidence-based sleep treatment. And none of this touches dosing, because there is no validated sleep protocol to dose — which is why we do not publish one.

The frustrating truth is that the interventions with the strongest evidence for deep sleep are not for sale in a vial. Sleep timing and regularity, morning light and evening dark, a cool bedroom, limiting alcohol and late caffeine, and protecting a consistent wake time do more for slow-wave sleep than any peptide on these lists — and they are what we walk through in our guide to increasing deep sleep. If you are chasing deeper sleep, that is where the return is. The peptides are, at best, an unproven detour.